{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-069067","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.731114+00:00","generated_at":"2026-06-01T06:18:21.912456+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet Bio gets FDA Fast Track for ADI-001 in lupus nephritis; Phase 1 starts this month","bullets":["FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III or IV lupus nephritis.","Company plans to initiate Phase 1 clinical study in lupus nephritis in June 2024.","ADI-001 previously showed CD19+ B-cell depletion in non-Hodgkin's lymphoma, similar to CAR T data in autoimmune diseases.","CEO Chen Schor cites urgent unmet need and plans to expand autoimmune program beyond lupus nephritis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-069067","json":"https://secwatch.observer/filing/0000950170-24-069067.json","markdown":"https://secwatch.observer/filing/0000950170-24-069067.md","text":"https://secwatch.observer/filing/0000950170-24-069067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024069067/0000950170-24-069067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024069067/acet-20240605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:18:21.912456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}